DK2478905T3 - Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler - Google Patents

Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler

Info

Publication number
DK2478905T3
DK2478905T3 DK12160638.8T DK12160638T DK2478905T3 DK 2478905 T3 DK2478905 T3 DK 2478905T3 DK 12160638 T DK12160638 T DK 12160638T DK 2478905 T3 DK2478905 T3 DK 2478905T3
Authority
DK
Denmark
Prior art keywords
carbonitrils
aminoquinolin
imatinib
treatment
resistant leukemia
Prior art date
Application number
DK12160638.8T
Other languages
Danish (da)
English (en)
Inventor
Becker Hewes
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39639071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2478905(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Llc filed Critical Wyeth Llc
Application granted granted Critical
Publication of DK2478905T3 publication Critical patent/DK2478905T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DK12160638.8T 2007-06-01 2008-05-30 Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler DK2478905T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93265007P 2007-06-01 2007-06-01
EP08769857A EP2152267A2 (en) 2007-06-01 2008-05-30 Treatment of imatinib resistant leukemia using 4-aminoquinoline-3-carbonitriles

Publications (1)

Publication Number Publication Date
DK2478905T3 true DK2478905T3 (da) 2014-06-30

Family

ID=39639071

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12160638.8T DK2478905T3 (da) 2007-06-01 2008-05-30 Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
DK15191756.4T DK3002009T3 (da) 2007-06-01 2008-05-30 Behandling af imatinib-resistent kronisk myeloid leukæmi, som har mutationen 1457t>c i bcrabl-genet, under anvendelse af forbindelsen bosutinib

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK15191756.4T DK3002009T3 (da) 2007-06-01 2008-05-30 Behandling af imatinib-resistent kronisk myeloid leukæmi, som har mutationen 1457t>c i bcrabl-genet, under anvendelse af forbindelsen bosutinib

Country Status (24)

Country Link
US (1) US11103497B2 (ja)
EP (4) EP2478905B1 (ja)
JP (3) JP5888853B2 (ja)
KR (1) KR101493543B1 (ja)
CN (1) CN101686973B (ja)
AU (1) AU2008260070B9 (ja)
BR (1) BRPI0812355A2 (ja)
CA (3) CA2964162C (ja)
CL (1) CL2008001577A1 (ja)
CY (2) CY1115251T1 (ja)
DK (2) DK2478905T3 (ja)
ES (2) ES2477567T3 (ja)
HK (1) HK1142812A1 (ja)
HU (1) HUE055524T2 (ja)
IL (1) IL202407A0 (ja)
MX (1) MX2009013069A (ja)
PA (1) PA8782301A1 (ja)
PL (2) PL3002009T3 (ja)
PT (2) PT3002009T (ja)
RU (1) RU2464026C2 (ja)
SI (2) SI3002009T1 (ja)
TW (1) TW200908982A (ja)
WO (1) WO2008150957A2 (ja)
ZA (1) ZA200908480B (ja)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2477567T3 (es) 2007-06-01 2014-07-17 Wyeth Llc Tratamiento de leucemia resistente a imatinib usando 4-aminoquinolin-3-carbonitrilos
EA023998B1 (ru) 2011-03-04 2016-08-31 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Аминохинолины в качестве ингибиторов киназ
TWI547494B (zh) 2011-08-18 2016-09-01 葛蘭素史克智慧財產發展有限公司 作為激酶抑制劑之胺基喹唑啉類
TW201425307A (zh) 2012-09-13 2014-07-01 Glaxosmithkline Llc 作為激酶抑制劑之胺基－喹啉類
AR092529A1 (es) 2012-09-13 2015-04-22 Glaxosmithkline Llc Compuesto de aminoquinazolina, composicion farmaceutica que lo comprende y uso de dicho compuesto para la preparacion de un medicamento
JP6301374B2 (ja) 2013-02-21 2018-03-28 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ キナーゼ阻害剤としてのキナゾリン類
KR101733665B1 (ko) 2015-05-06 2017-05-10 재단법인 지능형 바이오 시스템 설계 및 합성 연구단 진세노사이드 Ｆ1 또는 Ｒｇ3을 유효성분으로 포함하는 글리벡 내성 백혈병 예방 또는 치료용 약학 조성물
JP2022544700A (ja) * 2019-08-22 2022-10-20 バイオヘイブン・セラピューティクス・リミテッド 筋萎縮性側索硬化症および関連障害の治療のためにｔｄｐ－４３に結合する分子
CN115944636A (zh) * 2022-11-01 2023-04-11 华南师范大学 博舒替尼在抑制i-motif结构上的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
EP2343367A1 (en) 2001-10-05 2011-07-13 Novartis AG Mutated Abl kinase domains
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20050010780A1 (en) * 2003-07-09 2005-01-13 Kane John Richard Method and apparatus for providing access to personal information
RU2006113691A (ru) * 2003-11-06 2007-12-20 Вайет (Us) Применение 4-анилин-3-хинолинкарбонитрилов для лечения хронической миелогенной лейкемии (cml)
AU2006239860B2 (en) 2005-04-25 2012-01-19 Amgen Fremont Inc. Antibodies to myostatin
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
CA2615455A1 (en) 2005-07-15 2007-01-25 Bristol-Myers Squibb Company Methods of identifying and treating individuals exhibiting mutant src kinase polypeptides
US7635760B2 (en) 2005-10-06 2009-12-22 Eli Lilly And Company Anti-myostatin antibodies
US20100029676A1 (en) * 2005-11-04 2010-02-04 Sawyers Charles L T315a and f317i mutations of bcr-abl kinase domain
ES2477567T3 (es) 2007-06-01 2014-07-17 Wyeth Llc Tratamiento de leucemia resistente a imatinib usando 4-aminoquinolin-3-carbonitrilos

Also Published As

Publication number Publication date
EP3002009B1 (en) 2021-07-07
BRPI0812355A2 (pt) 2015-01-27
US20080318971A1 (en) 2008-12-25
SI2478905T1 (sl) 2014-07-31
EP2478905A2 (en) 2012-07-25
CA2868899A1 (en) 2008-12-11
MX2009013069A (es) 2010-03-17
CY1115251T1 (el) 2017-01-04
HK1142812A1 (en) 2010-12-17
PL2478905T3 (pl) 2014-10-31
KR101493543B1 (ko) 2015-02-13
HUE055524T2 (hu) 2021-11-29
US11103497B2 (en) 2021-08-31
PT2478905E (pt) 2014-07-16
TW200908982A (en) 2009-03-01
AU2008260070A1 (en) 2008-12-11
IL202407A0 (en) 2010-06-30
ZA200908480B (en) 2010-08-25
CA2964162C (en) 2019-12-31
SI3002009T1 (sl) 2021-09-30
ES2477567T3 (es) 2014-07-17
WO2008150957A2 (en) 2008-12-11
RU2464026C2 (ru) 2012-10-20
ES2881391T3 (es) 2021-11-29
JP2010529038A (ja) 2010-08-26
CA2868899C (en) 2017-06-13
CA2964162A1 (en) 2008-12-11
DK3002009T3 (da) 2021-08-02
JP2014111629A (ja) 2014-06-19
EP2478905B1 (en) 2014-05-14
RU2009144128A (ru) 2011-07-20
EP2152267A2 (en) 2010-02-17
PL3002009T3 (pl) 2021-12-13
EP3002009A2 (en) 2016-04-06
PA8782301A1 (es) 2009-01-23
EP2478905A3 (en) 2013-01-16
KR20100017983A (ko) 2010-02-16
AU2008260070B2 (en) 2011-08-18
CY1124391T1 (el) 2022-07-22
CA2688467C (en) 2015-05-12
EP2777704A3 (en) 2015-01-21
JP5888853B2 (ja) 2016-03-22
CA2688467A1 (en) 2008-12-11
PT3002009T (pt) 2021-08-02
EP2777704A2 (en) 2014-09-17
EP3002009A3 (en) 2016-07-06
AU2008260070B9 (en) 2012-01-19
CN101686973A (zh) 2010-03-31
WO2008150957A3 (en) 2009-08-06
CN101686973B (zh) 2013-06-19
CL2008001577A1 (es) 2008-07-25
JP2016074700A (ja) 2016-05-12

Similar Documents

Publication Publication Date Title
DK3289876T3 (da) Forbindelser til behandling af cancer
DK3517534T3 (da) Forbindelser, der er anvendelige til behandling af cancer
DK2350116T3 (da) Behandling af biofilm
DK2144923T3 (da) Behandlingsfremgangsmåder under anvendelse af glycopegyleret g-csf
DK2498771T3 (da) Anvendelse af bethanechol til behandling af xerostomi
DK2478907T3 (da) Sammensætninger til behandling af kræft
DK2478905T3 (da) Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
DK2356093T3 (da) Carbazolforbindelser og terapeutiske anvendelser af forbindelserne
DK2111555T3 (da) Diagnosticering af præeklampsi
DE602008003015D1 (de) Heterocyclische spiroverbindungen
BRPI0812803A2 (pt) Dessalinização
DK2358714T3 (da) Alkylcyclohexylethere af dihydrotetraazabenzoazulener
DK2209784T3 (da) Forbindelser til behandling af hepatitis C
DK2101805T3 (da) Integrinligander til anvendelse i behandling af cancer
DK2173831T3 (da) Brøndbehandling
DE112008002921A5 (de) Bohrfutter
DK2175849T3 (da) Behandling af melanomer
DK2118174T3 (da) Anvendelse af tocopherol
DK2181065T3 (da) Partialoxidation af carbonhydrider
DE502008000590D1 (de) Einstellvorrichtung
BRPI0817439A2 (pt) gaseificador
ATE506032T1 (de) Endoprothesenkomponente
ATE477711T1 (de) Defoliant
DE102007047112A8 (de) Strahlregler
BRPI0912237A2 (pt) conjunto de ajuste de estrangulador